Results 1 to 10 of about 23,410 (117)

Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

Nanomaterials, 2022
Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor
Masaki Kaibori, Hisashi Kosaka, Mitsuhiro Ebara   +2 more
exaly   +3 more sources

GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma

Journal of Advanced Research, 2023
Introduction: Lenvatinib has recently become available as the first-line therapy for advanced hepatocellular carcinoma (HCC), but its molecular mechanism in HCC remains largely unknown.
Sicong Zhu, Zhi-Qin Xie, Changzhen Shang
exaly   +3 more sources

ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma [PDF]

Cancer Biology & Therapy
Introduction Lenvatinib is a first-line therapy for hepatocellular carcinoma (HCC), but its clinical efficacy is limited by drug resistance. ABHD17C, a depalmitoylation enzyme involved in HCC progression, has not been investigated in lenvatinib response.
Linpei Wang, Jiawei Wang, Xiaoqiu Ma, Jinfa Huang, Yingming Sun, Chunfeng Shi, Jiahui Zhang, Peng Li, Hao Xu, Hongtan Lin, Wei Wang   +10 more
doaj   +2 more sources

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer

Gynecologic Oncology Reports, 2023
Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced ...
Clarissa Lam, Debra Sarasohn, Britta Weigelt, Dmitriy Zamarin   +3 more
doaj   +1 more source

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC

Hepatology Communications, 2022
Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown.
Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu   +6 more
doaj   +1 more source

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

Thoracic Cancer, 2022
Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma who developed ...
Yuto Terashima, Taiki Hakozaki, Susumu Takeuchi, Yukio Hosomi   +3 more
doaj   +1 more source

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS

Frontiers in Pharmacology, 2021
Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits
Jun Guo, Jun Guo, Jun Guo, Jun Guo, Peng Zhu, Peng Zhu, Peng Zhu, Peng Zhu, Zhi Ye, Mengke Wang, Mengke Wang, Mengke Wang, Mengke Wang, Haijun Yang, Haijun Yang, Haijun Yang, Haijun Yang, Shiqiong Huang, Shiqiong Huang, Shiqiong Huang, Shiqiong Huang, Yan Shu, Yan Shu, Yan Shu, Yan Shu, Yan Shu, Wei Zhang, Wei Zhang, Wei Zhang, Wei Zhang, Honghao Zhou, Honghao Zhou, Honghao Zhou, Honghao Zhou, Qing Li, Qing Li, Qing Li, Qing Li   +37 more
doaj   +1 more source

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Cancer Cell International, 2021
Background Lenvatinib and lenvatinib-based combination treatments are widely used in patients with unresectable hepatocellular carcinoma (uHCC) in clinical practice, but their curative effect and safety need further study in the real world.
Yun Zhu, Penghui Sun, Kunyuan Wang, Shuzhe Xiao, Yanling Cheng, Xiangzhao Li, Biao Wang, Jiancong Li, Wenxuan Yu, Yang Cheng   +9 more
doaj   +1 more source

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

Liver Cancer, 2021
Background: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore candidates
Keisuke Koroki, Naoya Kanogawa, Susumu Maruta, Sadahisa Ogasawara, Yotaro Iino, Masamichi Obu, Tomomi Okubo, Norio Itokawa, Takahiro Maeda, Masanori Inoue, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Yoshihiro Koma, Ryosaku Azemoto, Masanori Atsukawa, Ei Itobayashi, Kenji Ito, Nobuyuki Sugiura, Hideaki Mizumoto, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Kato   +39 more
doaj   +1 more source

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells

Scientific Reports, 2022
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC.
Xiaoping He, Yohko Hikiba, Yoshimasa Suzuki, Yoshinori Nakamori, Yushi Kanemaru, Makoto Sugimori, Takeshi Sato, Akito Nozaki, Makoto Chuma, Shin Maeda   +9 more
doaj   +1 more source